Onderzoeker
Quentin Lecocq
- Onderzoeksexpertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
- Trefwoorden:Geneeskunde
- Disciplines:Medische en gezondheidswetenschappen, Sociale wetenschappen
- Gebruikers van onderzoeksexpertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
Affiliaties
- Laboratorium voor Moleculaire en Cellulaire Therapie (Onderzoeksgroep)
Lid
Vanaf19 mrt 2021 → Heden - Basis (bio)-medische wetenschappen (Departement)
Lid
Vanaf1 jan 2018 → 31 dec 2021 - Basis (bio)-medische wetenschappen (Departement)
Lid
Vanaf1 okt 2016 → 30 sep 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf18 aug 2016 → 23 nov 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf31 aug 2014 → 21 jun 2016
Projecten
1 - 1 of 1
- Nanobody gemedieerde beeldvorming en blokkering van de inhiberende receptor LAG-3Vanaf1 jan 2018 → 31 dec 2021Financiering: FWO mandaten
Publicaties
1 - 10 van 21
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Auteurs: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pagina's: 1378-1384 - Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment(2023)
Auteurs: T Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout De Mey, Q Lecocq, Y De Vlaeminck, R M Awad, et al.
Pagina's: 751-758 - Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model(2022)
Auteurs: T Ertveldt, L De Beck, Kirsten De Ridder, Hanne Locy, Wout De Mey, Cleo Goyvaerts, Q Lecocq, Hannelore Ceuppens, Y De Vlaeminck, R M Awad, et al.
Pagina's: 1136-1148 - Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma(2022)
Auteurs: L De Beck, R M Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Y De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Q Lecocq, Edurne San José-Enériz, et al.
Pagina's: 1-15 - TNF-alpha-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy(2022)
Auteurs: Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, R M Awad, Stefaan Verhulst, Mathias Van Bulck, Y De Vlaeminck, Q Lecocq, Eva Reijmen, et al.
Pagina's: 1-15 - Emerging applications of nanobodies in cancer therapy(2022)
Auteurs: R M Awad, Fien Meeus, Hannelore Ceuppens, T Ertveldt, Heleen Hanssens, Q Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W M De Groof, et al.
Pagina's: 143-199 - Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer(2021)
Auteurs: Q Lecocq, P Debie, Janik Puttemans, R M Awad, L De Beck, T Ertveldt, Y De Vlaeminck, Cleo Goyvaerts, G Raes, M Keyaerts, et al.
- Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade(2021)
Auteurs: Quentin Lecocq, Robin Maximilian Awad, Yannick De Vlaeminck, Wout de Mey, Thomas Ertveldt, Cleo Goyvaerts, Geert Raes, Kris Thielemans, Marleen Keyaerts, Nick Devoogdt, et al.
Pagina's: 1638-1644 - Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade(2021)
Auteurs: R M Awad, Q Lecocq, Katty Zeven, T Ertveldt, L De Beck, Hannelore Ceuppens, Katrijn Broos, Y De Vlaeminck, Cleo Goyvaerts, Magali Verdonck, et al.
Pagina's: 172-182 - Developing nanobodies to advance immune checkpoint therapy that targets lymphocyteactivation gene 3(2021)
Auteurs: Q Lecocq, K Breckpot, Nick Devoogdt, M Keyaerts
Aantal pagina's: 170
Patenten
1 - 2 van 2
- Anti lag3 vhhs and their use (Inventor)
- Anti lag3 vhhs and their use (Inventor)